Retrophin Reports First Quarter 2019 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Retrophin (RTRX) Misses Q1 EPS by 6c, Revenues Miss
May 7, 2019 4:37 PM EDTRetrophin (NASDAQ: RTRX) reported Q1 EPS of ($0.63), $0.06 worse than the analyst estimate of ($0.57). Revenue for the quarter came in at $39.57 million versus the consensus estimate of $41 million.
Top-line data from the pivotal Phase 3 FORT Study of fosmetpantotenate in pantothenate kinase-associated neurodegeneration (PKAN) are anticipated in the third quarter of 2019, followed by anticipated submissions for a New Drug Application (NDA) in the U.S. and Marketing Authorization Application (MAA) in the EU in 2020The Company expects to make a... More